Key Metrics of Travere Therapeutics
Revenue$145M▲ 32.7% YoYFY 2023
Operating income−$388M▼ 21.4% YoY
Net profit−$111M▲ 60.0% YoY
Shareholders' equity$201M
Market cap$4.8BTVTX · $50.57
Open jobs1
About Travere Therapeutics
Company details
- Listed
- Nasdaq: TVTX
Company summary
Legal nameTravere Therapeutics Inc.
TickerTVTX
ExchangeNasdaq
CountryUnited States
SEC CIK0001438533
Listed since—
IndustryBiotechnology: Pharmaceutical Preparations
SectorOther Industries · Discovered Companies
Website—
US market & SEC filings
TVTX · Nasdaq · SEC CIK 0001438533
Last price · 30 Oct 2026
$50.57
−0.54%
Market cap$4.8B
P/E—On FY 2023 diluted EPS
Volume1,573,572
SectorHealth CareBiotechnology: Pharmaceutical Preparations
Country · IPOUnited States
TVTX share price
Premium
Annual results (SEC EDGAR)
Revenue, operating income, net income, EPS, cash flow, assets, liabilities, equity and debt for every year filed with the SEC are part of the premium plan.
Sign in to continue See plans & pricingVendor checks & payment capacity
Sign in with access to company financials to review vendor evidence.
Registered office and contact
Registered office—
GSTIN—
Email—
Website—
Members / shareholders—
Directors and key people
Directors are read from the MGT-7 annual return and AOC-4 signatories.
Charges (secured borrowings)
0 registered charges. Lenders, amounts and dates are part of the premium plan.
Statutory auditors
Auditors are read from the AOC-4 auditor's report section.
Business activities and related parties
Principal business activities and related-party transactions are read from MGT-7 and AOC-4 filings.
Filings
No filings on record yet.